Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 18, 2026, reports a significant regulatory milestone in Japan. The Japan Ministry of Health, Labour and Welfare (MHLW) has expanded the approval for GSK's RSV vaccine, Arexvy, to include adults aged 18 to 49 years at increased risk (AIR) for RSV disease. Additionally, prescribing information was updated to explicitly include immunocompromised (IC) patients as an increased risk group.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory announcement regarding product approval rather than a financial results report.
Material Changes and Regulatory Updates
- Expanded Indication in Japan: Arexvy is now approved for adults aged 18-49 years at increased risk, in addition to the existing approval for adults 60+ and adults 50-59 at increased risk.
- Updated Prescribing Information: The label now explicitly identifies immunocompromised patients as a target group for prevention.
- Global Context: The vaccine is approved in 70 countries for adults 60+ and in over 60 countries for adults 50-59 at increased risk. It is also approved for adults 18-49 at increased risk in the US and for all adults 18+ in the European Economic Area.
Outlook, Management Commentary, and Risks
Management Commentary: Sanjay Gurunathan, GSK Head of Vaccines and Infectious Diseases R&D, stated that this expanded approval is the first in Japan to cover all at-risk adults. He emphasized the vaccine's role in reducing severe outcomes for adults with chronic conditions such as cardiovascular disease, COPD, and asthma.
Clinical Support: The approval was supported by data from Phase IIIb trial NCT06389487, which demonstrated a non-inferior immune response in the 18-49 AIR cohort compared to adults 60+. Safety data from Phase IIb trial NCT05921903 supported the inclusion of immunocompromised patients. Common adverse events were injection site pain, myalgia, fatigue, arthralgia, and headache.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ due to risks described in GSK's 2025 Annual Report on Form 20-F and Q1 2026 results. The text notes that a protective immune response may not be elicited in all vaccinees.
Key Facts for Investor Verification
- Verify the commercial launch timeline and reimbursement status for the new 18-49 age indication in Japan.
- Confirm the size of the addressable market for adults aged 18-49 with chronic conditions in Japan.
- Monitor upcoming regulatory submissions in other geographies to expand the 18-49 AIR indication globally.
- Review the impact of this approval on GSK's overall vaccine portfolio revenue guidance in subsequent earnings reports.